Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NNZ 2591

Next Previous
Drug Profile

NNZ 2591

Alternative Names: ACP-2591; Cyclo-L-Glycyl-L-2-Allylproline; NNZ-2591

Latest Information Update: 07 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuren Pharmaceuticals
  • Developer ACADIA Pharmaceuticals; Neuren Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Alkenes; Antiparkinsonians; Behavioural disorder therapies; Cyclic peptides; Neuroprotectants; Nootropics; Piperazines; Pyrazines; Pyrroles; Small molecules; Vascular disorder therapies
  • Mechanism of Action Cell death inhibitors; Neuropeptide receptor modulators; Symporter modulators; Synaptic transmission modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pitt-Hopkins syndrome; Telomeric 22q13 Monosomy Syndrome; Prader-Willi syndrome; Angelman syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Angelman syndrome; Pitt-Hopkins syndrome; Prader-Willi syndrome; Telomeric 22q13 Monosomy Syndrome
  • Phase I Fragile X syndrome; Rett syndrome

Most Recent Events

  • 31 Jan 2024 Neuren Pharmaceuticals completes enrolment in its phase-II trial for Angelman syndrome (In children, In adolescents) in Australia (PO), (NCT05011851)
  • 31 Jan 2024 Neuren Pharmaceuticals plans phase-III trials for multiple indications
  • 18 Dec 2023 Efficacy and safety data from a phase II clinical trials in Telomeric 22q13 Monosomy Syndrome released by Neuren Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top